Skip to content

Influence of Profound Muscle Relaxation on Muscle Trauma and Postoperative Pulmonary Function

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01804933
Enrollment
72
Registered
2013-03-05
Start date
2012-07-31
Completion date
2013-08-31
Last updated
2013-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle Trauma, Postoperative Analgesic Demand, Postoperative Pulmonary Function, Profound Muscle Relaxation

Keywords

profound muscle relaxation, muscle trauma, postoperative analgesic demand, postoperative pulmonary function

Brief summary

Although deep anesthesia can produce skeleton muscle relaxation,unnecessary deep anesthesia often had adverse cardiac effects and was related to 2-year mortality in cancer patients.The use of muscle relaxants allowed the depth of anesthesia to be optimized.However, for many anesthesiologists,in fear of residual postoperative neuromuscular blockade,intraoprative administration of muscle relaxants had to be minimized in spite of poor surgical conditions. This study, however, is designed to test the hypothesis that profound neuromusclular blockade reduces muscle trauma caused by self-retaining retractor and thus cut down postoperative analgesic requirement.On the other hand,profound muscle relaxation can decrease postoperative diaphragmatic dysfunction and abdominal muscle trauma, which can improve postoperative pulmonary function.

Interventions

DRUGprofound neuromuscular blockade

Rocuronium dose will be infused to maintain a depth of NMB to PTC 1\ 2 intraoperatively

Sponsors

Ying Xiao
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* ASA 1\ 2,scheduled to undergo upper abdominal surgery by midline incision

Exclusion criteria

* neuromuscular disorder * history of malignant hyperthemia * allergy to medications used during general anesthesia

Design outcomes

Primary

MeasureTime frameDescription
degree of muscle trauma72h postoperativelyserum CK

Secondary

MeasureTime frameDescription
postoperative analgesic requirement7days postoperativelyconsumption of morphine

Other

MeasureTime frameDescription
postoperaive pulmonary function3days postoperativelyFEV1 FVC PEF

Countries

China

Contacts

Primary ContactYing Xiao, MD,PhD
xying2603@163.com13570521662

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026